As a contract research laboratory, we are acutely aware of the need to translate endpoints between animals and man. With this in mind, we believe our approach enables clients to do just that. Should you have any questions please do not hesitate to contact us, we are happy to help.

Automated Behaviour

Transpharmation has a suite of automated LABORAS (Laboratory Animal Behavior Observation Registration and Analysis System) cages which enable behavioural screening of small molecules, neuropeptides and antibodies in rodents (rats and mice). This bespoke system was developed by our partners Metris with input from us within the SmithKline Beecham organisation in the late 1990s.

LABORAS permits our scientists to measure the behaviour of animals in a ‘home cage’ environment with free access to food and water. The ability to acquire data from animals 24/7 for weeks at a time, in a light controlled environment, also allows for the assessment of circadian activity. This system has proved invaluable for objectively screening animals on multiple behavioural endpoints (e.g. activity, rearing, scratching, circling, feeding, drinking, wet dog shakes etc) following drug administration.

PK/PD studies

Laser Doppler

Transpharmation have invested in Laser Doppler for use in preclinical studies as a translational endpoint that can be taken into the clinic.

Laser Doppler Flowmetry is a non-invasive method of measuring, in real time, the continuous circulation of blood flow in the microvasculature of tissues and organs (e.g. skin). This has particular relevance as an end point in our acute inflammatory pain assays (e.g. UV burn, CFA-induced inflammation).

Inflammatory Pain

Human Tissues Studies

In order to deliver assays of translational relevance, Transpharmation have a partnership with a CNS focussed biobank, with access to tissue, fluids and full clinical histories of patients from a wide range of neurological and psychiatric disorders. These include MCI, Alzheimer’s disease and Parkinson’s disease.

Molecular Biomarkers

In addition to this, under our Gastrointestinal and Dermatology capabilities, we have access to a good clinical network that can supply tissue for studies directed to target validation, mechanism of action determination and efficacy assessment (e.g. stomach, colon and skin from ‘normal’ and diseased patient populations).